Visit Our Other Websites
empty
empty
CORONAVIRUS (COVID-19) RESOURCE CENTER Read More

TX SB 2308

Title: Relating to the establishment of a consortium to conduct United States Food and Drug Administration's drug development clinical trials with ibogaine to secure the administration's approval of the medication's use for treatment of opioid use disorder, co-occurring substance use disorder, and any other neurological or mental health conditions for which ibogaine demonstrates efficacy and to the administration of that treatment.
Author: Gary VanDeaver

Summary

Status
Sent to the Governor

Bill Documents
TX SB 2308 - Introduced
2025-03-11 - TX SB 2308 (Introduced)

TX SB 2308 - Senate Committee Report
2025-03-11 - TX SB 2308 (Senate Committee Report)
TX SB 2308 - Conference Committee Report
2025-03-11 - TX SB 2308 (Conference Committee Report)
TX SB 2308 - Engrossed
2025-03-11 - TX SB 2308 (Engrossed)
TX SB 2308 - House Committee Report
2025-03-11 - TX SB 2308 (House Committee Report)
TX SB 2308 - Engrossed
2025-03-11 - TX SB 2308 (Engrossed)
TX SB 2308 - Senate Committee Report
2025-03-11 - TX SB 2308 (Senate Committee Report)
TX SB 2308 - Introduced
2025-03-11 - TX SB 2308 (Introduced)
TX SB 2308 - House Amendment 1
2025-03-11 - TX SB 2308 (House Amendment 1)
TX SB 2308 - Enrolled
2025-03-11 - TX SB 2308 (Enrolled)

Add To Favorites

Author Details